Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Among authors: girvan ac. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Among authors: girvan ac. Eur J Cancer. 2018 Sep;100:135-136. doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30. Eur J Cancer. 2018. PMID: 29970352 No abstract available.
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. Zhu AX, et al. ESMO Open. 2020 Aug;5(4):e000797. doi: 10.1136/esmoopen-2020-000797. ESMO Open. 2020. PMID: 32817068 Free PMC article. Clinical Trial.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan AC, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely SC, Moser BA, Oliveira JM, Carlesi R, Walgren RA, Oh DY. Valle JW, et al. Among authors: girvan ac. Lancet Oncol. 2021 Oct;22(10):1468-1482. doi: 10.1016/S1470-2045(21)00409-5. Lancet Oncol. 2021. PMID: 34592180 Clinical Trial.
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA, Smit E, Carpeño Jde C, Leśniewski-Kmak K, Aerts J, Kraaij K, Visseren-Grul C, Dyachkova Y, Taipale K, Girvan A, Moro-Sibilot D. Schnabel PA, et al. Lung Cancer. 2012 Dec;78(3):263-9. doi: 10.1016/j.lungcan.2012.09.001. Epub 2012 Oct 4. Lung Cancer. 2012. PMID: 23040326 Clinical Trial.
Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer.
Pennella E, Obasaju CK, Pohl G, Peltz G, Girvan AC, Winfree KB, Martinez B, Marciniak M, Walker MS, Stepanski E, Schwartzberg LS, Adjei A. Pennella E, et al. Among authors: girvan ac. Clin Lung Cancer. 2013 Nov;14(6):726-35. doi: 10.1016/j.cllc.2013.06.011. Epub 2013 Jul 31. Clin Lung Cancer. 2013. PMID: 23910068
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Taipale K, Girvan AC, Visseren-Grul C, Schnabel PA. Moro-Sibilot D, et al. Among authors: girvan ac. Lung Cancer. 2015 May;88(2):215-22. doi: 10.1016/j.lungcan.2015.02.011. Epub 2015 Feb 21. Lung Cancer. 2015. PMID: 25748103
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Girvan A, Visseren-Grul C, Schnabel PA. Moro-Sibilot D, et al. Lung Cancer. 2015 Dec;90(3):427-32. doi: 10.1016/j.lungcan.2015.11.011. Epub 2015 Nov 10. Lung Cancer. 2015. PMID: 26791802
18 results